EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integration of single‐cell and bulk transcriptomics reveals the association of manganese metabolism‐related genes with prognosis and immune infiltration in lung adenocarcinoma

Hongliang Li, Shuzhen Wei, Wei Li, Junxia Sun, Yi Wang iD

Clinical & Translational Immunology · 2026-03 · 15 (3)

DOI: 10.1002/cti2.70085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 11.03.2026. Verfasst von Hongliang Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy The Affiliated Huai'an Hospital of Xuzhou Medical University Huai'an City Jiangsu Province China. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung adenocarcinoma (LUAD) is associated with a poor prognosis. Manganese metabolism plays a critical role in antitumor immunity. The prognostic significance of manganese metabolism–related genes (MRGs) in LUAD remains unclear.

Methods

Single‐cell RNA sequencing and TCGA transcriptomic data were integrated to identify expressed MRGs. Cell subpopulations were defined using AUCell scoring. A prognostic signature was constructed using univariate Cox regression, LASSO regression and multivariate Cox analysis. A nomogram incorporating the manganese metabolism–related risk score (MRS) and clinical variables was developed, and predictive performance was evaluated using receiver operating characteristic curves. Immune infiltration patterns and drug sensitivity were further analysed.

Results

A robust prognostic model based on nine genes, including KLRF1, demonstrated strong predictive performance. Patients in the high‐MRS group exhibited increased M1 macrophage infiltration and shorter overall survival, whereas the low‐MRS group was characterised by enrichment of resting dendritic cells. Drug sensitivity analyses suggested that JQ1 and Vorinostat may be more effective in low‐MRS patients, while Pevonedistat and LCL161 may be preferable for high‐MRS patients. In vitro experiments confirmed that high PTMA expression promoted malignant phenotypes in LUAD cells, and that combined JQ1 treatment and PTMA knockdown exerted synergistic antitumor effects.

Conclusions

We established and validated a prognostic signature based on nine MRGs. The synergistic antitumor effects of JQ1 and PTMA suppression were verified. This model provides a novel biomarker framework and therapeutic guidance for prognostic assessment and personalised treatment in LUAD.

Schlagwörter

Stichwörter der Autor:innen

bulk RNA‐seqlung adenocarcinomamanganese metabolismprognosisscRNA‐seq

Autor:innen und Institutionen

  • Department of Radiotherapy The Affiliated Huai'an Hospital of Xuzhou Medical University Huai'an City Jiangsu Province China.
  • Department of Oncology Huai'an 82 Hospital Huai'an City Jiangsu Province China.
  • Department of Respiratory and Critical Care Medicine The Affiliated Huai'an Hospital of Xuzhou Medical University Huai'an City Jiangsu Province China.

ORCID-Profile: Yi Wang

Zitieren

APA

Li, H., Wei, S., Li, W., Sun, J., & Wang, Y. (2026). Integration of single‐cell and bulk transcriptomics reveals the association of manganese metabolism‐related genes with prognosis and immune infiltration in lung adenocarcinoma. Clinical & Translational Immunology, 15(3). https://doi.org/10.1002/cti2.70085

Vancouver

Li H, Wei S, Li W, Sun J, Wang Y. Integration of single‐cell and bulk transcriptomics reveals the association of manganese metabolism‐related genes with prognosis and immune infiltration in lung adenocarcinoma. Clinical & Translational Immunology. 2026;15(3). doi:10.1002/cti2.70085

BibTeX
@article{Li2026,
  author = {Li, Hongliang and Wei, Shuzhen and Li, Wei and Sun, Junxia and Wang, Yi},
  title = {Integration of single‐cell and bulk transcriptomics reveals the association of manganese metabolism‐related genes with prognosis and immune infiltration in lung adenocarcinoma},
  journal = {Clinical & Translational Immunology},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1002/cti2.70085}
}
Kostenlos starten →